Dianthus Therapeutics Inc. (DNTH) - Net Assets
Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) has net assets worth $493.40 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($530.92 Million) and total liabilities ($37.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DNTH cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $493.40 Million |
| % of Total Assets | 92.93% |
| Annual Growth Rate | 55.96% |
| 5-Year Change | 185.74% |
| 10-Year Change | N/A |
| Growth Volatility | 145.69 |
Dianthus Therapeutics Inc. - Net Assets Trend (2016–2025)
This chart illustrates how Dianthus Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Dianthus Therapeutics Inc. for the complete picture of this company's asset base.
Annual Net Assets for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual net assets of Dianthus Therapeutics Inc. from 2016 to 2025. For live valuation and market cap data, see market value of Dianthus Therapeutics Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $493.40 Million | +39.98% |
| 2024-12-31 | $352.48 Million | +108.73% |
| 2023-12-31 | $168.87 Million | +129.27% |
| 2022-12-31 | $73.66 Million | -57.34% |
| 2021-12-31 | $172.67 Million | +19.99% |
| 2020-12-31 | $143.91 Million | +1.92% |
| 2019-12-31 | $141.19 Million | -3.06% |
| 2018-12-31 | $145.65 Million | +189.44% |
| 2017-12-31 | $50.32 Million | +456.53% |
| 2016-12-31 | $9.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dianthus Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32700900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $43.00K | 0.01% |
| Other Comprehensive Income | $489.00K | 0.10% |
| Other Components | $829.60 Million | 168.14% |
| Total Equity | $493.40 Million | 100.00% |
Dianthus Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Dianthus Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Choice Hotels International Inc
NYSE:CHH
|
$4.63 Billion |
|
Dottikon Es Holding AG
SW:DESN
|
$4.63 Billion |
|
Indofood Cbp Sukses Makmur Tbk
JK:ICBP
|
$4.63 Billion |
|
Companhia Energética de Minas Gerais
F:CID
|
$4.63 Billion |
|
Wacker Chemie AG
XETRA:WCH
|
$4.63 Billion |
|
CCOOP Group Co Ltd
SHE:000564
|
$4.62 Billion |
|
Budimex S.A.
WAR:BDX
|
$4.62 Billion |
|
Alkermes Plc
NASDAQ:ALKS
|
$4.62 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dianthus Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 352,477,000 to 493,401,000, a change of 140,924,000 (40.0%).
- Net loss of 162,337,000 reduced equity.
- Share repurchases of 317,000 reduced equity.
- New share issuances of 272,268,000 increased equity.
- Other comprehensive income increased equity by 383,000.
- Other factors increased equity by 30,927,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-162.34 Million | -32.9% |
| Share Repurchases | $317.00K | -0.06% |
| Share Issuances | $272.27 Million | +55.18% |
| Other Comprehensive Income | $383.00K | +0.08% |
| Other Changes | $30.93 Million | +6.27% |
| Total Change | $- | 39.98% |
Book Value vs Market Value Analysis
This analysis compares Dianthus Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.37x to 6.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $4.09 | $87.42 | x |
| 2017-12-31 | $22.76 | $87.42 | x |
| 2018-12-31 | $69.95 | $87.42 | x |
| 2019-12-31 | $61.03 | $87.42 | x |
| 2020-12-31 | $52.42 | $87.42 | x |
| 2021-12-31 | $50.28 | $87.42 | x |
| 2022-12-31 | $19.66 | $87.42 | x |
| 2023-12-31 | $32.77 | $87.42 | x |
| 2024-12-31 | $10.58 | $87.42 | x |
| 2025-12-31 | $13.05 | $87.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dianthus Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7973.33%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-32.90%) is above the historical average (-44.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -104.30% | 0.00% | 0.00x | 1.25x | $-10.34 Million |
| 2017 | -70.53% | 0.00% | 0.00x | 1.08x | $-40.52 Million |
| 2018 | -39.49% | 0.00% | 0.00x | 1.08x | $-72.08 Million |
| 2019 | -54.37% | 0.00% | 0.00x | 1.14x | $-90.89 Million |
| 2020 | -52.07% | 0.00% | 0.00x | 1.12x | $-89.33 Million |
| 2021 | -7.59% | -888.14% | 0.01x | 1.10x | $-30.38 Million |
| 2022 | -38.66% | -443.76% | 0.08x | 1.13x | $-35.84 Million |
| 2023 | -25.79% | -1541.22% | 0.02x | 1.06x | $-60.44 Million |
| 2024 | -24.11% | -1362.77% | 0.02x | 1.06x | $-120.22 Million |
| 2025 | -32.90% | -7973.33% | 0.00x | 1.08x | $-211.68 Million |
Industry Comparison
This section compares Dianthus Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dianthus Therapeutics Inc. (DNTH) | $493.40 Million | -104.30% | 0.08x | $4.63 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more